Search

Annemarie Hedwig Ralston

from Charlottesville, VA
Age ~85
Get Report
Also known as:
Annemarie H Ralston, Annemarie Te Ralston, Annemarie Cotr Ralston, Annemarie M Ralston, Anne Marie Ralston, Annemarie Ralston Co
Related to:
Byron G Barefoot, 77Pamela B Ralston, 50Leonard H Ralston, 88Thomas A Eagleson, 54Christopher J Ralston, 68Alexa RalstonSheri L Ralston, 65Leonard M Ralston, 53
Connected to:
Alice J Ralston, 96Anita B Ralston, 56Ann M Ralston, 58Bob E Ralston, 87Cathy A Ralston, 72Charlotte S Ralston, 85Connie J Ralston, 50Corinne A Ralston, 39Daniel J Ralston, 49Drew L Ralston, 29

Annemarie Ralston Phones & Addresses

  • Charlottesville, VA
  • Washington, DC
  • 6520 Greentree Rd, Bethesda, MD 20817 (301) 469-8819
  • 6520 Greentree Rd, Bethesda, MD 20817

Work

Position: Professional/Technical

Education

Degree: Graduate or professional degree

Languages

English

Interests

Collecting Antiques • Exercise • Sweepstakes • Home Improvement • Collecting Art • Reading • Gourmet Cooking • Sports • The Arts • Fishing • Home Decoration • Health • Collecting Coins • Diy • Cooking • Skiing • Gardening • Cruises • Sewing • Outdoors • Electronics • Crafts • Fitness • Music • Family Values • Movies • Collecting • Christianity • Kids • Medicine • Diet • Automobiles • Woodwork • Travel • Wine • Boating • Investing • Traveling

Resumes

Resumes

Annemarie Ralston Photo 1

Annemarie Ralston

View page
Location:
6520 Greentree Rd, Bethesda, MD 20817
Interests:
Collecting Antiques
Exercise
Sweepstakes
Home Improvement
Collecting Art
Reading
Gourmet Cooking
Sports
The Arts
Fishing
Home Decoration
Health
Collecting Coins
Diy
Cooking
Skiing
Gardening
Cruises
Sewing
Outdoors
Electronics
Crafts
Fitness
Music
Family Values
Movies
Collecting
Christianity
Kids
Medicine
Diet
Automobiles
Woodwork
Travel
Wine
Boating
Investing
Traveling
Languages:
English

Publications

Us Patents

Method For The Production Of Pure Virally Inactivated Butyrylcholinesterase

View page
US Patent:
7365173, Apr 29, 2008
Filed:
Feb 4, 2002
Appl. No.:
10/061233
Inventors:
Annemarie H. Ralston - Bethesda MD, US
Billy L. Kolen - Springdale MD, US
David John Hammond - Laytonsvile MD, US
Assignee:
American National Red Cross - Washington DC
International Classification:
C07K 1/14
C07K 1/18
C07K 1/22
US Classification:
530412, 530416, 530422
Abstract:
The present invention provides a method for purifying butyrylcholinesterase from various biological fluids. Biological fluids include, e. g. , blood, blood fractions, plasma, and bioreactor broths, and other such mixtures containing butyrylcholinesterase. In one embodiment, the invention provides a method for the production of purified, virally inactivated butyrylcholinesterase by contacting a biological fluid containing butyrylcholinesterase with a cationic exchange chromatography material, with an affinity chromatography material, and treating the fluid with solvent detergent. The resulting purified butyrylcholinesterase can also be subjected to a pasteurization step, and formulated in a sodium chloride/sodium phosphate solution for storage or lyophilization.

Plasma Protein-Binding Ligands

View page
US Patent:
20030212253, Nov 13, 2003
Filed:
Apr 14, 2003
Appl. No.:
10/414524
Inventors:
David Hammond - Laytonsville MD, US
Julia Lathrop - Falls Church VA, US
Annemarie Ralston - Bethesda MD, US
Timothy Hayes - N. Potomac MD, US
Iwona Fijalkowska - Rockville MD, US
Assignee:
The American National Red Cross - Falls Church VA
International Classification:
C07K005/06
A61K038/06
US Classification:
530/330000, 514/018000
Abstract:
The invention provides an isolated or purified peptide that binds at least one plasma protein. In one embodiment, the isolated or purified peptide binds to fibrinogen, comprises no more than 10 amino acids, and comprises an amino acid sequence Xaa-Xaa-Xaa-Xaa-Xaa, an amino acid sequence Gly-Xaa-Arg-Xaa, or an amino acid sequence selected from specific amino acid sequences provided herein. Alternatively, the isolated or purified protein binds to al proteinase inhibitor and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase. The peptide comprises no more than 10 amino acids and comprises an amino acid sequence Xaa-Xaa-Xaa-His-Xaa-Xaa, and amino acid sequence His-Xaa-Xaa-Xaa-Xaa-Xaa, or an amino acid sequence selected from specific amino acid sequences provided herein. In addition, the invention provides isolated or purified peptide that binds to von Willebrand Factor. The peptide comprises an amino acid sequence Xaa-Xaa-Xaa, an amino acid sequence Tyr-Leu-Xaa-Xaa-Xaa-Thr, or an amino acid sequence selected from specific amino acid sequences provided herein.

Method For The Production Of Pure Virally Inactivated Butyrylcholinesterase

View page
US Patent:
20090093038, Apr 9, 2009
Filed:
Mar 13, 2008
Appl. No.:
12/076107
Inventors:
Annemarie H. Ralston - Bethesda MD, US
Billy L. Kolen - Springdale MD, US
David John Hammond - Laytonsville MD, US
Assignee:
American National Red Cross - Washington DC
International Classification:
C12N 9/99
C12N 9/14
US Classification:
435184, 435195
Abstract:
The present invention provides a method for purifying butyrylcholinesterase from various biological fluids. Biological fluids include, e.g., blood, blood fractions, plasma, and bioreactor broths, and other such mixtures containing butyrylcholinesterase. In one embodiment, the invention provides a method for the production of purified, virally inactivated butyrylcholinesterase by contacting a biological fluid containing butyrylcholinesterase with a cationic exchange chromatography material, with an affinity chromatography material, and treating the fluid with solvent detergent. The resulting purified butyrylcholinesterase can also be subjected to a pasteurization step, and formulated in a sodium chloride/sodium phosphate solution for storage or lyophilization.

Plasma Protein-Binding Ligands

View page
US Patent:
20090258834, Oct 15, 2009
Filed:
May 24, 2007
Appl. No.:
11/802730
Inventors:
David J. Hammond - Laytonsville MD, US
Julia Tait Lathrop - Falls Church VA, US
Annemarie Ralston - Bethesda MD, US
Timothy K. Hayes - N. Potomac MD, US
Iwona Fijalkowska - Rockville MD, US
Assignee:
The American National Red Cross - Falls Church VA
International Classification:
A61K 38/06
G01N 33/573
C12N 9/14
G01N 33/566
C07K 7/06
A61K 38/08
C07K 5/08
C07K 14/435
C07K 14/75
C07K 14/575
US Classification:
514 17, 435 78, 435195, 436501, 514 18, 530329, 530330, 530331, 530359, 530382, 530383
Abstract:
The invention provides an isolated or purified peptide that binds at least one plasma protein. In one embodiment, the isolated or purified peptide binds to fibrinogen, comprises no more than 10 amino acids, and comprises an amino acid sequence Xaa-Xaa-Xaa-Xaa-Xaa, an amino acid sequence Gly-Xaa-Arg-Xaa, or an amino acid sequence selected from specific amino acid sequences provided herein. Alternatively, the isolated or purified protein binds to α1 proteinase inhibitor and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase. The peptide comprises no more than 10 amino acids and comprises an amino acid sequence Xaa-Xaa-Xaa-His-Xaa-Xaa, and amino acid sequence His-Xaa-Xaa-Xaa-Xaa-Xaa, or an amino acid sequence selected from specific amino acid sequences provided herein. In addition, the invention provides isolated or purified peptide that binds to von Willebrand Factor. The peptide comprises an amino acid sequence Xaa-Xaa-Xaa, an amino acid sequence Tyr-Leu-Xaa-Xaa-Xaa-Thr, or an amino acid sequence selected from specific amino acid sequences provided herein.

Method For Purification Of Alpha-1 Proteinase Inhibitor

View page
US Patent:
60938048, Jul 25, 2000
Filed:
Sep 24, 1998
Appl. No.:
9/159461
Inventors:
Annemarie H. Ralston - Bethesda MD
William H. Drohan - Springfield VA
Assignee:
American National Red Cross - Falls Church VA
International Classification:
C07K 1400
A61K 3514
A23J 100
US Classification:
530416
Abstract:
The methods of the present invention provide a simple means for separating active and inactive Alpha Proteinase Inhibitor (API). The methods further provide means for purifying API at high yield (>70%), and at levels of purity (>90%) and activity (>90%) not heretofore available. Moreover, the methods of the present invention are simple (i. e. , two chromatographic steps) and efficient; and are thus especially suitable to large scale purification processes. These methods will contribute substantially to alleviating the unmet demand for API for therapeutic purposes.

Pathogen Inactivating Compositions For Disinfecting Biological Fluids

View page
US Patent:
61067733, Aug 22, 2000
Filed:
Sep 24, 1998
Appl. No.:
9/159460
Inventors:
Shirley I. Miekka - Gaithersburg MD
William N. Drohan - Springfield VA
Annemarie Ralston - Bethesda MD
Hao Xue - North Potomac MD
Assignee:
American National Red Cross - Falls Church VA
International Classification:
A61L 900
US Classification:
422 28
Abstract:
The present invention is directed to pathogen inactivating compositions that can be used to disinfect various biological fluids, such as blood, blood fractions, and the like. The compositions are suitable for disinfecting biological fluids containing valuable, but labile, components such as proteins without destroying the desired properties of such components. The pathogen inactivating compositions of the present invention are produced by contacting water or an aqueous solution with iodinated matrix material. The compositions can be pre-formulated and stored for subsequent use in disinfecting a wide range of biological fluids.

Activation Of Pure Prothrombin To Thrombin With About 30% To About 40% Sodium Citrate

View page
US Patent:
62455486, Jun 12, 2001
Filed:
Mar 9, 2000
Appl. No.:
9/522010
Inventors:
Annemarie H. Ralston - Bethesda MD
William N. Drohan - Springfield VA
Assignee:
American National Red Cross - Falls Church VA
International Classification:
C12N 974
A61K 3848
US Classification:
435214
Abstract:
A method for the production of thrombin from pure prothrombin is provided by converting pure prothrombin by treating pure prothrombin with sodium citrate in the absence of additional coagulation factors. Preferrably, a solution is used containing about 30% to about 40% sodium citrate.
Control profile
Annemarie Hedwig Ralston from Charlottesville, VA, age ~85 Get Report